Table 6.
Small molecules targeting Bcl-2-family proteins in clinical development [89].
| Type | Small Molecule Inhibitor | Disease | |
|---|---|---|---|
| Phase I | Mcl-1 protein inhibitor | AMG-176 AZD-5991 |
Multiple myeloma |
| Hematological cancer | |||
| S-64315 (MIK-665) | Diffuse large B-cell lymphoma, multiple myeloma | ||
| S-64315 (MIK-665) | Myelodysplastic syndrome, Acute myeloid leukemia (AML) | ||
| Bcl-2 protein inhibitor | Venetoclax | Non-Hodgkin lymphoma, myelodysplastic syndrome | |
| BCL-201 (S-55746) | Mantle cell lymphoma, follicular lymphoma | ||
| BCL-201 (S-55746) | Myelodysplastic syndrome, CLL, AML, NHL | ||
| Bcl-2, Bcl-xL inhibitor | APG-1252 | Tumor, small cell lung cancer | |
| AT-101 | Multiple myeloma | ||
| Navitoclax | Acute lymphoblastic leukemia | ||
| Phase II | Bcl-2 protein inhibitor | Venetoclax | Diffuse large B cell lymphoma, B cell lymphoma, myelodysplastic syndrome (suspended), follicular lymphoma |
| Venetoclax | DLBCL, B cell lymphoma, myelodysplastic syndrome (suspended), Waldenström macroglobulinemia, hematological neoplasm, follicular lymphoma | ||
| Bcl-2, Bcl-xL inhibitor | Navitoclax | Myelofibrosis | |
| Phase III | Bcl-2 protein inhibitor | Venetoclax | Multiple myeloma, acute myeloid leukemia |
| Venetoclax | Multiple myeloma, AML, mantle cell lymphoma | ||
| Venetoclax | Chronic lymphocytic leukemia [31] |